Second-line injectable drugs for rifampicin-resistant tuberculosis: better the devil we know?

MLA

Tahseen, Sabira, et al. “Second-Line Injectable Drugs for Rifampicin-Resistant Tuberculosis: Better the Devil We Know?” Journal of Antimicrobial Chemotherapy (JAC), vol. 76, no. 4, Apr. 2021, pp. 831–35. EBSCOhost, https://doi.org/10.1093/jac/dkaa489.

APA

Tahseen, S., Deun, A. V., Jong, B. C. de, Decroo, T., Van Deun, A., & de Jong, B. C. (2021). Second-line injectable drugs for rifampicin-resistant tuberculosis: better the devil we know? Journal of Antimicrobial Chemotherapy (JAC), 76(4), 831–835. https://doi.org/10.1093/jac/dkaa489

Chicago

Tahseen, Sabira, Armand Van Deun, Bouke C de Jong, Tom Decroo, Armand Van Deun, and Bouke C de Jong. 2021. “Second-Line Injectable Drugs for Rifampicin-Resistant Tuberculosis: Better the Devil We Know?” Journal of Antimicrobial Chemotherapy (JAC) 76 (4): 831–35. doi:10.1093/jac/dkaa489.